Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurine + Sintilimab + Chemotherapy in Advanced Gastric Cancer
NCT06123455Phase 2Unknown
- Sponsor
- Tangdu Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric cancer (GC) (2 arms), sponsored by Tangdu Hospital. Primary endpoints: Progression-free survival at 24 months and Overall survival at 24 months. Status: unknown.
02
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06123455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123455.